{"id":"ak156","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL924","moleculeType":"Small molecule","molecularWeight":"272.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AK156 binds to programmed death receptor 1 (PD-1) on T cells, preventing interaction with its ligands (PD-L1 and PD-L2) expressed on tumor cells and immune cells. This blockade releases the brake on T cell-mediated immunity, allowing enhanced proliferation, activation, and cytotoxic function against cancer cells. The mechanism is similar to other PD-1 inhibitors used in immuno-oncology.","oneSentence":"AK156 is a humanized monoclonal antibody that blocks the PD-1 checkpoint pathway to enhance anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:34.500Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation)"}]},"trialDetails":[{"nctId":"NCT01522521","phase":"PHASE3","title":"Study of AK156 in Primary Osteoporosis Patients","status":"COMPLETED","sponsor":"Asahi Kasei Pharma Corporation","startDate":"2012-02","conditions":"Osteoporosis","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AK156","genericName":"AK156","companyName":"Asahi Kasei Pharma Corporation","companyId":"asahi-kasei-pharma-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AK156 is a humanized monoclonal antibody that blocks the PD-1 checkpoint pathway to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}